On 05 de nov. de 2025, TECH reported earnings of 0.42 USD per share (EPS) for Q1 26, missing the estimate of 0.42 USD, resulting in a -2.03% surprise. Revenue reached 286.56 milhão, compared to an expected 297.05 milhão, with a -3.53% difference. The market reacted with a -1.90% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 16 analistas forecast an EPS of 0.44 USD, with revenue projected to reach 295.99 milhão USD, implying an aumentar of 4.76% EPS, and aumentar of 3.29% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Bio-Techne Corp.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Bio-Techne Corp. reported EPS of $0.42, missing estimates by -2.03%, and revenue of $286.56M, -3.53% below expectations.
How did the market react to Bio-Techne Corp.'s Q1 2026 earnings?
The stock price moved down -1.9%, changed from $61.10 before the earnings release to $59.94 the day after.
When is Bio-Techne Corp. expected to report next?
The next earning report is scheduled for 03 de fev. de 2026.
What are the forecasts for Bio-Techne Corp.'s next earnings report?
Based on 16
analistas, Bio-Techne Corp. is expected to report EPS of $0.44 and revenue of $295.99M for Q2 2026.